ZLAB Zai Lab Limited

32.24
0  0%
Previous Close 32.24
Open
Price To Book 7.5
Market Cap 1,881,394,313
Shares 58,355,903
Volume 0
Short Ratio
Av. Daily Volume 234,437

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data released August 24, 2018. Primary endpoint not met.
Fugan (ZL-3101)
Eczema
Phase 2 interim data released September 2018.
ZL-2301
Second-line Hepatocellular carcinoma (HCC)
Phase 3 dosing initiated - noted June 29. 2018.
ZL-2306 (niraparib)
First-line maintenance therapy for platinum-responsive ovarian cancer
China NDA filing announced December 12, 2018.
ZL-2306 (niraparib)
Recurrent platinum-sensitive ovarian cancer
Phase 3 futility analysis due 1H 2020.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 3 trial initiation announced August 28, 2018.
ZL-2306 (niraparib)
Small cell lung cancer
Phase 3 trial initiation announced April 4, 2019 with top-line data due 2H 2020.
ETX2514SUL
Acinetobacter baumannii infections

Latest News

  1. Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer
  2. Do Insiders Own Lots Of Shares In Zai Lab Limited (NASDAQ:ZLAB)?
  3. Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
  4. Zai Lab Appoints Valeria Fantin, Ph.D., as Chief Scientific Officer
  5. Zai Lab Announces Presentations at June Conferences
  6. Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections
  7. Zai Lab Announces Participation at Upcoming May Conferences
  8. Here’s What Hedge Funds Think About Zai Lab Limited (ZLAB)
  9. Zai Lab Announces Pricing of Public Offering of American Depositary Shares
  10. 3 Top Chinese Stocks to Watch in May
  11. Zai Lab Announces Proposed Public Offering of American Depositary Shares
  12. Zai Lab to Host Analyst & Investor Day on April 30, 2019
  13. Did Zai Lab's (NASDAQ:ZLAB) Share Price Deserve to Gain 38%?
  14. Zai Lab Announces Presentations at March Conferences
  15. Zai Lab Announces Financial Results and Corporate Update for Full Year 2018
  16. Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript
  17. Zai Lab to Announce Full Year 2018 Financial Results
  18. Zai Lab to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  19. The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut